NICE recommends Amgen's carfilzomib with dexamethasone for RMM treatment

The National Institute for Health and Care Excellence (NICE) in the UK has recommended US-based biopharmaceutical company Amgen's Kyprolis (Carfilzomib) in combination with dexamethasone as an option for treating adults with relapsed multiple myeloma …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news